Ninety-five participants with DSM-IV borderline personality disorder were randomly assigned to receive 150 mg/day of quetiapine ( the low-dosage group ; N = 33 ) , 300 mg/day of quetiapine ( the moderate-dosage group ; N = 33 ) , or placebo ( N = 29 ) .